Business and Finance

In this week’s Pharma Pulse, the launch of the Ember Cube 2, exclusive policy insights from Asembia AXS26, a record-breaking prescription spending outlook for 2026 and more.

Live from Asembia AXS26, Jessica Lovett explains what real world evidence and data matters most in making decisions around specialty medicines.

Avalere Health analysts map the converging pressures reshaping the drug pricing and distribution landscape ahead of November.

Rahul Shah and Mack MacKenzie explain how to unlock the ROI that rules-based systems have left on the table.

In this week’s Pharma Pulse, GEODIS’ cold chain expansion in the Midwest, a potential multi-billion dollar shift in cell therapy, and the White House’s new push for psychedelic mental health treatments.

Pharma importers can apply for tariff reimbursements through the US Customs and Border Protection’s online portal.

Lilly’s $7B deal for Kelonia aims to turn complex cell therapy into a simple injection, bypassing the slow, costly lab work of current cancer treatments.

Fran Gregory, VP of Emerging Therapies at Cardinal Health, discusses key findings from the company's 2026 Advanced Therapy Report.

Charley Maxwell explains why Annex 21 is not just a regulatory hurdle, but a key commercial risk point.

Roel van den Akker examines how the industry might evolve its trade, distribution, and payer strategies to scale GLP-1s for mass demand.

In today’s Pharma Pulse, Walgreens reshapes pharmacist roles, pharmacies expand injectable access, GoodRx and Eli Lilly broaden GLP-1 access, radiopharma investment grows, and AbbVie signs a $745 million Haisco licensing deal.

Roel van den Akker evaluates how blockbuster GLP-1s may shift broader commercialization trends.

In a Q&A, Traci Miller discusses the evolving role of hub services as well as their commercial value.

Lilly's Foundayo and Zepbound KwikPen are now available on GoodRx for self-pay access.

In this week’s Pharma Pulse, tariffs reshape drug supply, a fragile ceasefire tests global pharma, Wegovy goes higher-dose, and patients still can't get appointments fast enough.

Amber Hussain-Siddique says operational discipline in inventory and logistics is the vital, yet overlooked, key to sustaining low-cost generic drug supplies in the U.S.

Nareda Mills explains why patient services teams are more than support, but strategic drivers for brands.

Pharma can optimize DTP strategies by leveraging data on affordability and patient behavior.

New Benefit 360 and Direct Fund models aim to bridge the gap between clinical eligibility and employer-sponsored coverage.

Workflow alignment, e-prescribing integration, and behavior change strategies are critical to reducing friction across the direct-to-patient ecosystem.

Jordan Armstrong outlines how adaptable DTP programs can reduce barriers and accelerate patient access to therapy.

Shifting cost dynamics and infrastructure capabilities are prompting manufacturers to reassess traditional distribution channels.

Brok Vandersteen explains how life sciences companies can strategically adopt DTP models for better patient access and commercial success.

Kristine McGaughey, vice president of Implementation at ConnectiveRx, shares her insights on timing, strategy, and planning to ensure a smooth therapy launch.

Kroger will offer the Zepbound KwikPen at its participating retail pharmacies.